Frustrating to see they haven't updated since April 2022. Can't they even report if they completed enrollment and are still on target to have completion by October for the planned 24 patients?
I can understand not releasing more interim results for fear of introducing bias (increasing placebo effect) in results for crossover patients, but at least a status update would be nice.
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-646
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |